This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Interactions

Authoring team

Amiodarone is metabolised by hepatic cytochrome P450 3A4(CYP 3A4) isoenzyme:

  • concomitant administration of CYP 3A4 inhibitors should either be avoided or used only with caution
  • CYP 3A4 inducers (e.g. carbamazepine, rifampicin) may lead to a reduction in amiodarone's plasma concentration and therefore reduce efficacy
  • amiodarone itself inhibits CYP 3A4 and therefore will increase plasma concentrations of drugs such as ciclosporin, phenytoin and verapamil

Other important interactions with amiodarone include:

  • potentiation of the effects of warfarin (inhibits metabolism via CYP 3A4)

  • reduces excretion of digoxin (leads to increased plasma concentration)

  • contra-indicated with other drugs that prolong the QT interval (e.g. disopyramide, quinidine, procainamide); only specialists should co-prescribe and monitor such drug therapy

Reference:

  1. Drug and Therapeutics Bulletin (2003), 41 (2), 9-12.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.